Literature DB >> 6021164

Propranolol as ocular hypotensive agent.

C I Phillips, G Howitt, D J Rowlands.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6021164      PMCID: PMC506370          DOI: 10.1136/bjo.51.4.222

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  19 in total

1.  Inhibition and excitation of reticulo-rumen contractions following the introduction of acids into the rumen and abomasum.

Authors:  R W ASH
Journal:  J Physiol       Date:  1959-06-23       Impact factor: 5.182

2.  THE EFFECT OF ADRENALIN IN GLAUCOMA SIMPLEX.

Authors:  H AASVED
Journal:  Acta Ophthalmol (Copenh)       Date:  1964

3.  Effect of 2% levo-rotary epinephrine on the intraocular pressure of the glaucomatous eye.

Authors:  L L GARNER; W W JOHNSTONE; E J BALLINTINE; M E CARROLL
Journal:  AMA Arch Ophthalmol       Date:  1959-08

4.  Adrenergic blockade of the mammalian heart by a dichloro analogue of isoproterenol.

Authors:  N C MORAN; M E PERKINS
Journal:  J Pharmacol Exp Ther       Date:  1958-11       Impact factor: 4.030

5.  Tonometer calibration; an attempt to remove discrepancies found in the 1954 calibration scale for Schiotz tonometers.

Authors:  J S FRIEDENWALD
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1957 Jan-Feb

6.  Effects of superior cervical ganglionectomy on aqueous humor dynamics.

Authors:  W A LIEB; D GUERRY; L J ELLIS
Journal:  AMA Arch Ophthalmol       Date:  1958-07

7.  Treatment of ocular hypertension by adrenalin and diverse sympathomimetic amines.

Authors:  R WEEKERS; Y DELMARCELLE; J GUSTIN
Journal:  Am J Ophthalmol       Date:  1955-11       Impact factor: 5.258

8.  Influence of the sympathetic nervous system on the intra-ocular pressure and vascular circulation of the eye.

Authors:  D P GREAVES; E S PERKINS
Journal:  Br J Ophthalmol       Date:  1952-05       Impact factor: 4.638

9.  Inhibition of adrenaline oxidation by borate.

Authors:  E M TRAUTNER; M MESSER
Journal:  Nature       Date:  1952-01-05       Impact factor: 49.962

10.  [Origin of ocular hypertension in primary glaucoma].

Authors:  H GOLDMANN
Journal:  Ann Ocul (Paris)       Date:  1951-12
View more
  44 in total

1.  Beta-blockers in the treatment of chronic simple glaucoma.

Authors: 
Journal:  Br Med J       Date:  1976-01-24

Review 2.  Side effects and contraindications of beta-receptor blocking agents.

Authors:  H Lydtin
Journal:  Klin Wochenschr       Date:  1977-05-01

3.  Atenolol eye drops.

Authors:  C I Phillips; M Macdonald; S M Gore; P M Cullen
Journal:  Br Med J       Date:  1976-12-11

Review 4.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

5.  Ocular hypotensive effect of atenolol (Tenormin, I.C.I.). A new beta-adrenergic blocker.

Authors:  M J Elliot; P M Cullen; C I Phillips
Journal:  Br J Ophthalmol       Date:  1975-06       Impact factor: 4.638

6.  Comparison of ocular hypotensive effects of acetazolamide and atenolol.

Authors:  M J Macdonald; S M Gore; P M Cullen; C I Phillips
Journal:  Br J Ophthalmol       Date:  1977-05       Impact factor: 4.638

7.  Effect of topical atenolol on intraocular pressure.

Authors:  K Wettrell; M Pandolfi
Journal:  Br J Ophthalmol       Date:  1977-05       Impact factor: 4.638

8.  Acute effect of metipranolol on the retinal circulation.

Authors:  S Wolf; E Werner; K Schulte; M Reim
Journal:  Br J Ophthalmol       Date:  1998-08       Impact factor: 4.638

9.  Penetration of five beta-adrenergic antagonists into the rabbit eye after ocular instillation.

Authors:  C Schmitt; V J Lotti; J C Le Douarec
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1981

10.  Atenolol versus adrenaline eye drops and an evaluation of these two combined.

Authors:  C I Phillips; S M Gore; P M Gunn
Journal:  Br J Ophthalmol       Date:  1978-05       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.